All AbMole products are for research use only, cannot be used for human consumption.
Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent HIV-1 inhibitor with an IC50 of 0.38 μM. Diphyllin is active against vesicular stomatitis virus (VSV) and influenza virus. Diphyllin is a vacuolar type H+-ATPase (V-ATPase) inhibitor with an IC50 value of 17 nM and inhibits lysosomal acidification in human osteoclasts. Diphyllin inhibits NO production with an IC50 of 50 μM and has anticancer and anti-inflammatory activities.
| Molecular Weight | 380.35 |
| Formula | C21H16O7 |
| CAS Number | 22055-22-7 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Xin-Ya Xu, et al. Chin J Nat Med. Anti-HIV lignans from Justicia procumbens
| Related HIV Protease Products |
|---|
| Atazanavir Sulfate
Atazanavir sulfate (BMS-232632, Reyataz) is an azapeptide inhibitor of HIV-1 protease. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. |
| Bevirimat
Bevirimat (BVM), also known as PA-457 or MPC-4326, is a novel Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor. |
| Lopinavir
Lopinavir (ABT-378) is a potent protease inhibitor. |
| Ritonavir
Ritonavir is an HIV protease inhibitor used in the study of HIV infection and AIDS. Ritonavir (ABT 538) |
| Delavirdine mesylate
Delavirdine mesylate is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
